ArticleScandinavian journal of immunology2026
From Validation to Clinical Interpretation: A Flow Cytometric Th17-Cell Assay for STAT1- and STAT3-Related Inborn Errors of Immunity.
Article in Scandinavian journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Th17-cells are crucial for defence against fungal and bacterial infections and deficiency characterises certain inborn errors of immunity (IEI), including STAT3-related Hyper IgE syndrome (HIES) and STAT1-related Chronic Mucocutaneous Candidiasis (CMC). Standardised methods for clinical Th17-cell quantification are limited. We developed a flow cytometric assay for quantifying Th17-cells in peripheral blood based on PMA/ionomycin stimulation and intracellular IL-17 labeling and evaluated its precision, robustness and longitudinal stability. A reference interval was established in 51 healthy adults and the impact of age and sex was assessed. The assay was applied to 31 patients carrying STAT1 or STAT3 variants or presenting phenotypes for which Th17-cell quantification is informative. Diagnostic performance was analysed using receiver operating characteristic (ROC) curves and Matthew's Correlation Coefficients (MCC). The assay showed high intra- and inter-assay precision (CV 5.1% and 10%) and Th17-cell fractions remained stable after 72 h of post-fixation storage. Delayed pre-fixation reduced precision. Age and sex did not significantly influence Th17-cell fractions, supporting a unified Th17-cell reference interval of T-helper cells [0.21%-1.7%]. Compared with healthy controls, Th17-cell fractions were significantly lower in patients with STAT3 variants, patients with HIES or with both. ROC and MCC analyses indicated that Th17-cell fractions above 0.44% reliably excluded pathogenic variants or associated phenotypes in all patient groups. This validated Th17-cell assay is robust, reproducible and suitable for clinical use. It can guide genetic testing in IEI by identifying patients with Th17-cell deficiencies and excluding variants or phenotypes unlikely to be causative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.